

Felicita Andreotti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3092758/publications.pdf>

Version: 2024-02-01

214
papers

40,982
citations

17440

63
h-index

2385

198
g-index

229
all docs

229
docs citations

229
times ranked

32719
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2016, 37, 267-315. | 2.2 | 5,890 |
| 2 | 2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2019, 40, 87-165. | 2.2 | 4,537 |
| 3 | 2013 ESC guidelines on the management of stable coronary artery disease. <i>European Heart Journal</i> , 2013, 34, 2949-3003. | 2.2 | 3,915 |
| 4 | Guidelines on the management of valvular heart disease (version 2012). <i>European Heart Journal</i> , 2012, 33, 2451-2496. | 2.2 | 3,465 |
| 5 | Guidelines on the diagnosis and management of acute pulmonary embolism. <i>European Heart Journal</i> , 2008, 29, 2276-2315. | 2.2 | 2,645 |
| 6 | 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Heart Journal</i> , 2018, 39, 213-260. | 2.2 | 2,246 |
| 7 | Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. <i>European Heart Journal</i> , 2008, 29, 2909-2945. | 2.2 | 2,128 |
| 8 | Lipoprotein(a) as a cardiovascular risk factor: current status. <i>European Heart Journal</i> , 2010, 31, 2844-2853. | 2.2 | 1,392 |
| 9 | Guidelines on the management of valvular heart disease (version 2012). <i>European Journal of Cardio-thoracic Surgery</i> , 2012, 42, S1-S44. | 1.4 | 1,313 |
| 10 | Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. <i>European Heart Journal</i> , 2011, 32, 1345-1361. | 2.2 | 993 |
| 11 | Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. <i>European Heart Journal</i> , 2009, 30, 2769-2812. | 2.2 | 735 |
| 12 | Increased Proinflammatory Cytokines in Patients With Chronic Stable Angina and Their Reduction By Aspirin. <i>Circulation</i> , 1999, 100, 793-798. | 1.6 | 541 |
| 13 | Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke. <i>American Journal of Cardiology</i> , 1988, 62, 635-637. | 1.6 | 432 |
| 14 | 2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 55, 4-90. | 1.4 | 402 |
| 15 | Vitamin K antagonists in heart disease: Current status and perspectives (Section III). <i>Thrombosis and Haemostasis</i> , 2013, 110, 1087-1107. | 3.4 | 347 |
| 16 | Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. <i>European Heart Journal</i> , 2011, 32, 1854-1864. | 2.2 | 343 |
| 17 | Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1566. | 7.4 | 339 |
| 18 | Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting. <i>Thrombosis and Haemostasis</i> , 2010, 103, 13-28. | 3.4 | 292 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. <i>BMJ, The</i> , 2015, 350, h1618-h1618. | 6.0 | 279 |
| 20 | The -174G/C Interleukin-6 Polymorphism Influences Postoperative Interleukin-6 Levels and Postoperative Atrial Fibrillation. Is Atrial Fibrillation an Inflammatory Complication?. <i>Circulation</i> , 2003, 108, 195II-199. | 1.6 | 264 |
| 21 | Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25â€¦307 patients. <i>European Heart Journal</i> , 2006, 27, 519-526. | 2.2 | 263 |
| 22 | 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 53, 34-78. | 1.4 | 261 |
| 23 | New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1413-1425. | 2.8 | 257 |
| 24 | Meta-Analysis of Impact of Different Types and Doses of Statins on New-Onset Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2013, 111, 1123-1130. | 1.6 | 239 |
| 25 | Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function. <i>European Heart Journal</i> , 2005, 26, 1196-1204. | 2.2 | 235 |
| 26 | Bleeding risk assessment and management in atrial fibrillation patients. <i>Thrombosis and Haemostasis</i> , 2011, 106, 997-1011.. | 3.4 | 234 |
| 27 | Insulin-Like Growth Factor-1 as a Vascular Protective Factor. <i>Circulation</i> , 2004, 110, 2260-2265. | 1.6 | 231 |
| 28 | Preinfarction Angina as a Predictor of More Rapid Coronary Thrombolysis in Patients with Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 1996, 334, 7-12. | 27.0 | 228 |
| 29 | Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>European Heart Journal</i> , 2010, 31, 1311-1318. | 2.2 | 216 |
| 30 | Antiplatelet agents for the treatment and prevention of atherothrombosis. <i>European Heart Journal</i> , 2011, 32, 2922-2932. | 2.2 | 203 |
| 31 | Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. <i>Europace</i> , 2011, 13, 723-746. | 1.7 | 197 |
| 32 | Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. <i>BMJ, The</i> , 2013, 347, f6530-f6530. | 6.0 | 194 |
| 33 | Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2015, 36, ehv304. | 2.2 | 175 |
| 34 | General mechanisms of coagulation and targets of anticoagulants (Section I). <i>Thrombosis and Haemostasis</i> , 2013, 109, 569-579. | 3.4 | 165 |
| 35 | Relation of the âˆ”174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization. <i>American Journal of Cardiology</i> , 2001, 88, 1125-1128. | 1.6 | 161 |
| 36 | Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. <i>American Heart Journal</i> , 1994, 127, 607-612. | 2.7 | 157 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Parenteral anticoagulants in heart disease: Current status and perspectives (Section II). <i>Thrombosis and Haemostasis</i> , 2013, 109, 769-786. | 3.4 | 154 |
| 38 | Age dependence of ischaemic heart syndromes and the contribution of haemostatic deviations. <i>Fibrinolysis</i> , 1992, 6, 3-4. | 0.5 | 152 |
| 39 | Optimal Timing of Coronary Invasive Strategy in Non-â€œST-Segment Elevation Acute Coronary Syndromes. <i>Annals of Internal Medicine</i> , 2013, 158, 261. | 3.9 | 151 |
| 40 | Aspirin Therapy in Primary Cardiovascular Disease Prevention. <i>Journal of the American College of Cardiology</i> , 2014, 64, 319-327. | 2.8 | 150 |
| 41 | Circadian Variation of Fibrinolytic Activity in Blood. <i>Chronobiology International</i> , 1991, 8, 336-351. | 2.0 | 146 |
| 42 | Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. <i>Thrombosis and Haemostasis</i> , 2014, 112, 781-782. | 3.4 | 142 |
| 43 | Inflammatory gene polymorphisms and ischaemic heart disease: review of population association studies. <i>British Heart Journal</i> , 2002, 87, 107-112. | 2.1 | 133 |
| 44 | Survival Benefits of Invasive Versus Conservative Strategies in Heart Failure in Patients With Reduced Ejection Fraction and Coronary Artery Disease. <i>Circulation: Heart Failure</i> , 2017, 10, . | 3.9 | 123 |
| 45 | Rate-control vs. rhythm-control in patients with atrial fibrillation: a meta-analysis. <i>European Heart Journal</i> , 2005, 26, 2000-2006. | 2.2 | 120 |
| 46 | Sex differences in mechanisms, presentation and management of ischaemic heart disease. <i>Atherosclerosis</i> , 2015, 241, 157-168. | 0.8 | 113 |
| 47 | Hypercoagulable States in Cardiovascular Disease. <i>Circulation</i> , 2008, 118, 2286-2297. | 1.6 | 110 |
| 48 | Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. <i>European Heart Journal</i> , 2018, 39, 1672-1686f. | 2.2 | 106 |
| 49 | Markedly reduced insulin-like growth factor-1 in the acute phase of myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2001, 38, 26-32. | 2.8 | 94 |
| 50 | Female sex as an independent risk factor for stroke in atrial fibrillation: Possible mechanisms. <i>Thrombosis and Haemostasis</i> , 2014, 111, 385-391. | 3.4 | 90 |
| 51 | Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials. <i>EuroIntervention</i> , 2011, 7, 985-994. | 3.2 | 87 |
| 52 | Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2017, 38, ehw454. | 2.2 | 86 |
| 53 | Meta-Analysis of Time-Related Benefits of Statin Therapy in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2014, 113, 1753-1764. | 1.6 | 80 |
| 54 | Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2021, 42, 4638-4651. | 2.2 | 80 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A "state-of-the-art" paper. <i>European Heart Journal</i> , 2014, 35, 2213-2223. | 2.2 | 78 |
| 56 | Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. <i>Nature Reviews Cardiology</i> , 2019, 16, 113-130. | 13.7 | 73 |
| 57 | Erythropoietin in heart and vessels: focus on transcription and signalling pathways. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 26, 183-187. | 2.1 | 72 |
| 58 | Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm. A Joint Consensus Document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. <i>European Journal of Heart Failure</i> , 2012, 14, 681-695. | 7.1 | 71 |
| 59 | Comprehensive Meta-Analysis of Safety and Efficacy of Bivalirudin Versus Heparin With or Without Routine Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Coronary Syndrome. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 201-213. | 2.9 | 69 |
| 60 | Genetic control of postoperative systemic inflammatory reaction and pulmonary and renal complications after coronary artery surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2003, 126, 1107-1112. | 0.8 | 66 |
| 61 | Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease. <i>American Heart Journal</i> , 2005, 149, 832-839. | 2.7 | 65 |
| 62 | Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1009-1022. | 3.4 | 65 |
| 63 | 2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 1125. | 0.6 | 57 |
| 64 | Women and coronary disease. <i>Heart</i> , 2008, 94, 108-116. | 2.9 | 55 |
| 65 | Relation Between Platelet Response to Exercise and Coronary Angiographic Findings in Patients With Effort Angina. <i>Circulation</i> , 2003, 107, 1378-1382. | 1.6 | 54 |
| 66 | Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor-1 and von Willebrand factor in acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 1990, 16, 1553-1560. | 2.8 | 53 |
| 67 | The left atrial appendage: from embryology to prevention of thromboembolism. <i>European Heart Journal</i> , 2017, 38, ehw159. | 2.2 | 53 |
| 68 | Diurnal variation in platelet inhibition by clopidogrel. <i>Platelets</i> , 2011, 22, 579-587. | 2.3 | 52 |
| 69 | Reduced levels of insulin-like growth factor-1 in patients with angina pectoris, positive exercise stress test, and angiographically normal epicardial coronary arteries. <i>American Journal of Cardiology</i> , 2002, 89, 973-975. | 1.6 | 49 |
| 70 | Heart-Kidney Interactions in Ischemic Syndromes. <i>Circulation</i> , 2004, 109, e31-2; author reply e31-2. | 1.6 | 48 |
| 71 | Atherothrombotic Disorders. <i>Circulation</i> , 2005, 111, 1855-1863. | 1.6 | 48 |
| 72 | Low-grade exercise enhances platelet aggregability in patients with obstructive coronary disease independently of myocardial ischemia. <i>American Journal of Cardiology</i> , 2001, 87, 16-20. | 1.6 | 46 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Leading Avoidable Cause of Premature Deaths Worldwide: Case for Obesity. American Journal of Medicine, 2013, 126, 97-98. | 1.5 | 46 |
| 74 | Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation. Europace, 2015, 17, 1007-1017. | 1.7 | 46 |
| 75 | Adjusted Indirect Meta-Analysis of Aspirin Plus Warfarin at International Normalized Ratios 2 to 3 Versus Aspirin Plus Clopidogrel After Acute Coronary Syndromes. American Journal of Cardiology, 2007, 99, 1637-1642. | 1.6 | 45 |
| 76 | Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 677-686. | 3.0 | 45 |
| 77 | Preoperative C-reactive protein level and outcome following coronary surgery. European Journal of Cardio-thoracic Surgery, 2002, 22, 521-526. | 1.4 | 44 |
| 78 | Implantable Cardioverter-Defibrillators for Primary Prevention in Patients With Ischemic or Nonischemic Cardiomyopathy. Annals of Internal Medicine, 2017, 167, 103. | 3.9 | 43 |
| 79 | Early spontaneous intermittent myocardial reperfusion during acute myocardial infarction is associated with augmented thrombogenic activity and less myocardial damage. Journal of the American College of Cardiology, 1995, 26, 662-667. | 2.8 | 42 |
| 80 | Increased circulating C-reactive protein and macrophage-colony stimulating factor are complementary predictors of long-term outcome in patients with chronic coronary artery disease. European Heart Journal, 2005, 26, 1618-1624. | 2.2 | 40 |
| 81 | Temporal Relation Between Ischemic Episodes and Activation of the Coagulation System in Unstable Angina. Circulation, 1996, 93, 2121-2127. | 1.6 | 38 |
| 82 | Four-year trends in oral anticoagulant use and declining rates of ischemic stroke among 194,030 atrial fibrillation patients drawn from a sample of 12 million people. American Heart Journal, 2020, 220, 12-19. | 2.7 | 37 |
| 83 | Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome: A meta-analysis of randomized trials. Atherosclerosis, 2012, 222, 1-7. | 0.8 | 36 |
| 84 | Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients. Europace, 2020, 22, 538-546. | 1.7 | 36 |
| 85 | Homocysteine and risk of cardiovascular disease. Journal of Thrombosis and Thrombolysis, 2000, 9, 13-21. | 2.1 | 35 |
| 86 | Pregnancy associated plasma protein-A and coronary atherosclerosis: marker, friend, or foe?The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.. European Heart Journal, 2005, 26, 2075-2076. | 2.2 | 35 |
| 87 | Coronary Artery Disease and Type 2 Diabetes: A Proteomic Study. Diabetes Care, 2020, 43, 843-851. | 8.6 | 34 |
| 88 | Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 86-93. | 3.0 | 34 |
| 89 | Body fat and cardiovascular risk: understanding the obesity paradox. European Heart Journal, 2008, 30, 752-754. | 2.2 | 32 |
| 90 | Aspirin, but not heparin, suppresses the transient increase in thromboxane biosynthesis associated with cardiac catheterization or coronary angioplasty. Journal of the American College of Cardiology, 1993, 21, 1377-1381. | 2.8 | 29 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Drug-coated balloons in treatment of in-stent restenosis: a meta-analysis of randomised controlled trials. <i>Clinical Research in Cardiology</i> , 2013, 102, 279-287. | 3.3 | 29 |
| 92 | Normothermia does not improve postoperative hemostasis nor does it reduce inflammatory activation in patients undergoing primary isolated coronary artery bypass. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2002, 123, 1092-1100. | 0.8 | 28 |
| 93 | Effectiveness of multiple bolus administration of tissue-type plasminogen activator in acute myocardial infarction. <i>American Journal of Cardiology</i> , 1990, 65, 1051-1056. | 1.6 | 27 |
| 94 | Serum Lipoprotein(a) Level Is Related to Thrombin Generation and Spontaneous Intermittent Coronary Occlusion in Patients With Acute Myocardial Infarction. <i>Circulation</i> , 1996, 94, 2072-2076. | 1.6 | 27 |
| 95 | Effect of propranolol (long-acting) on the circadian fluctuation of tissue-plasminogen activator and plasminogen activator inhibitor-1. <i>American Journal of Cardiology</i> , 1991, 68, 1295-1299. | 1.6 | 26 |
| 96 | Antithrombotic therapy in the early phase of non-ST-elevation acute coronary syndromes: a systematic review and meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 43-56. | 3.0 | 26 |
| 97 | Pregnancy-Associated Plasma Protein A as Predictor of Outcome in Patients With Suspected Acute Coronary Syndromes. <i>Circulation</i> , 2004, 109, e211-2; author reply e211-2. | 1.6 | 25 |
| 98 | Update on phase II studies of erythropoietin in acute myocardial infarction. Rationale and design of Exogenous erythroPoietin in Acute Myocardial Infarction: New Outlook aNd Dose Association Study (EPAMINONDAS). <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 28, 489-495. | 2.1 | 25 |
| 99 | Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0168726. | 2.5 | 25 |
| 100 | The C807T/G873A polymorphism in the platelet glycoprotein Ia gene and the risk of acute coronary syndrome in the Italian population. <i>British Journal of Haematology</i> , 2001, 114, 150-154. | 2.5 | 24 |
| 101 | Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease. <i>Thrombosis and Haemostasis</i> , 2016, 115, 685-711. | 3.4 | 24 |
| 102 | Development and Validation of a Practical Model to Identify Patients at Risk of Bleeding After TAVR. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1196-1206. | 2.9 | 24 |
| 103 | 4G/5G PAI-1 Promoter Polymorphism and Acute-Phase Levels of PAI-1 Following Coronary Bypass Surgery: A Prospective Study. <i>Journal of Thrombosis and Thrombolysis</i> , 2003, 16, 149-154. | 2.1 | 22 |
| 104 | Age-Related 2-Year Mortality After Transcatheter Aortic Valve Replacement: the YOUNG TAVR Registry. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1457-1466. | 3.0 | 19 |
| 105 | Dual therapy with direct oral anticoagulants significantly increases the risk of stent thrombosis compared to triple therapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 128-129. | 3.0 | 19 |
| 106 | Glycoprotein IIb/IIIa inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the OPTIMIZE-IT™ pilot randomized study. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, 245-251. | 1.5 | 18 |
| 107 | Safety and efficacy of P2Y ₁₂ inhibitor monotherapy in patients undergoing percutaneous coronary interventions. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 9-21. | 2.4 | 18 |
| 108 | IGF-1 and Macrovascular Complications of Diabetes: Alternative interpretations of recently published data. <i>Diabetes Care</i> , 2003, 26, 1653-1654. | 8.6 | 17 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 109 | Inflammation, genetics, and ischemic heart disease: focus on the major histocompatibility complex (MHC) genes. <i>Cytokine</i> , 2005, 29, 187-196. | 3.2 | 17 |
| 110 | Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a review. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 47-54. | 3.0 | 16 |
| 111 | Marked von Willebrand factor and factor VIII elevations in severe acute respiratory syndrome coronavirus-2-positive, but not severe acute respiratory syndrome coronavirus-2-negative, pneumonia: a caseâ€“control study. <i>Blood Coagulation and Fibrinolysis</i> , 2021, 32, 285-289. | 1.0 | 16 |
| 112 | Thrombin generation after fast or prolonged regimens of tissue-type plasminogen activator. <i>Lancet, The</i> , 1993, 342, 937-938. | 13.7 | 15 |
| 113 | Perioperative aspirin therapy in non-cardiac surgery: A systematic review and meta-analysis of randomized controlled trials. <i>International Journal of Cardiology</i> , 2018, 258, 59-67. | 1.7 | 14 |
| 114 | From angiotensin-converting enzyme 2 disruption to thromboinflammatory microvascular disease: A paradigm drawn from COVID-19. <i>International Journal of Cardiology</i> , 2021, 326, 243-247. | 1.7 | 14 |
| 115 | Direct Oral Anticoagulants in Asian Patients with Atrial Fibrillation: Consensus Recommendations by the Asian Pacific Society of Cardiology on Strategies for Thrombotic and Bleeding Risk Management. <i>European Cardiology Review</i> , 2021, 16, e23. | 2.2 | 14 |
| 116 | Ischaemic preconditioning. <i>Lancet, The</i> , 1996, 348, 204. | 13.7 | 13 |
| 117 | Antibiotic therapy for severe bacterial infections: correlation between the inhibitory quotient and outcome. <i>International Journal of Antimicrobial Agents</i> , 2004, 23, 120-128. | 2.5 | 13 |
| 118 | Pregnancy-Associated Plasma Protein-A and Acute Coronary Syndromes: Cause or Consequence?. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1583-1584. | 2.8 | 13 |
| 119 | Endogenous serum erythropoietin and no-reflow in patients with ST-elevation myocardial infarction. <i>European Journal of Clinical Investigation</i> , 2011, 41, 1210-1219. | 3.4 | 13 |
| 120 | Randomised trials and meta-analyses of double vs triple antithrombotic therapy for atrial fibrillation-ACS/PCI: A critical appraisal. <i>IJC Heart and Vasculature</i> , 2020, 28, 100524. | 1.1 | 13 |
| 121 | Efficacy and safety of dual-pathway inhibition in patients with cardiovascular disease: a meta-analysis of 49 802 patients from 7 randomized trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 519-528. | 3.0 | 13 |
| 122 | Ticlopidine and aspirin fail to suppress the increased platelet aggregability that follows percutaneous coronary interventions. <i>Journal of Thrombosis and Thrombolysis</i> , 2000, 10, 265-269. | 2.1 | 12 |
| 123 | Clinical conundrums in antithrombotic therapy management: A Delphi Consensus panel. <i>International Journal of Cardiology</i> , 2017, 249, 249-256. | 1.7 | 12 |
| 124 | Early anticoagulation in the current management of NSTEMI-ACS: Evidence, guidelines, practice and perspectives. <i>International Journal of Cardiology</i> , 2019, 275, 39-45. | 1.7 | 12 |
| 125 | Comparative efficacy and safety of anticoagulant strategies for acute coronary syndromes. <i>Thrombosis and Haemostasis</i> , 2015, 114, 933-944. | 3.4 | 11 |
| 126 | Adherence and Persistence with Once-Daily vs Twice-Daily Direct Oral Anticoagulants Among Patients with Atrial Fibrillation: Real-World Analyses from the Netherlands, Italy and Germany. <i>Drugs - Real World Outcomes</i> , 2022, 9, 199-209. | 1.6 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2021, 143, 673-684. | 1.6 | 10 |
| 128 | Anti-inflammatory therapy in ischaemic heart disease: from canakinumab to colchicine. <i>European Heart Journal Supplements</i> , 2021, 23, E13-E18. | 0.1 | 10 |
| 129 | Serum homocysteine, MTHFR gene polymorphism, and carotid intimal-medial thickness in NIDDM subjects. <i>Journal of Thrombosis and Thrombolysis</i> , 1999, 8, 207-212. | 2.1 | 9 |
| 130 | Role of PAPP-A in atherothrombosis: Messages to take home. <i>Atherosclerosis</i> , 2009, 203, 353-354. | 0.8 | 9 |
| 131 | Aspirin and the prevention of a common disease: Colorectal cancer. <i>International Journal of Cardiology</i> , 2017, 248, 394-395. | 1.7 | 9 |
| 132 | Metabolomic correlates of coronary atherosclerosis, cardiovascular risk, both or neither. Results of the 2 Å– 2 phenotypic CAPIRE study. <i>International Journal of Cardiology</i> , 2021, 336, 14-21. | 1.7 | 9 |
| 133 | Effectiveness and safety of a single intravenous Bolus injection of tissue-type plasminogen activator in acute myocardial infarction. <i>American Journal of Cardiology</i> , 1992, 69, 1393-1398. | 1.6 | 8 |
| 134 | Potential of Fibrinolytic Therapy in Acute Myocardial Infarction: Expanding the Role of ACE-Inhibitors. <i>Thrombosis and Haemostasis</i> , 2002, 88, 176-178. | 3.4 | 8 |
| 135 | Prothrombotic response to coronary angioplasty in patients with unstable angina and raised C-reactive protein. <i>Journal of Thrombosis and Thrombolysis</i> , 2002, 14, 131-138. | 2.1 | 8 |
| 136 | Stent Thrombosis With Dual Antithrombotic Therapy in Atrial Fibrillation—ACS/PCI Trials. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1727-1728. | 2.8 | 8 |
| 137 | Prevalence, clinical impact and costs of hyperkalaemia: Special focus on heart failure. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13551. | 3.4 | 8 |
| 138 | Preinfarction Angina and Improved Reperfusion of the Infarct-related Artery. <i>Thrombosis and Haemostasis</i> , 1999, 82, 68-72. | 3.4 | 8 |
| 139 | The G20210A Prothrombin Mutation and the Physicians' Health Study. <i>Circulation</i> , 2000, 101, E207-8. | 1.6 | 7 |
| 140 | Relation between nitric oxide metabolites and haemoglobin concentrations in patients with ischaemic heart disease. <i>Heart</i> , 2005, 93, 255-257. | 2.9 | 7 |
| 141 | Proteomics, metabolomics and progenitor cells in acute coronary syndromes. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 22, 85-88. | 2.1 | 7 |
| 142 | Predictors of exercise-induced platelet reactivity in patients with chronic stable angina. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, 891-897. | 1.5 | 7 |
| 143 | Baseline von Willebrand factor plasma levels and no-reflow phenomenon after primary percutaneous coronary intervention for ST segment elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2010, 145, 230-232. | 1.7 | 7 |
| 144 | Anemia contributes to cardiovascular disease through reductions in nitric oxide. <i>Journal of Applied Physiology</i> , 2017, 122, 414-417. | 2.5 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 145 | G20210A Prothrombin Gene Polymorphism and Extent of Coronary Disease. <i>Thrombosis and Haemostasis</i> , 2000, 84, 142-143. | 3.4 | 6 |
| 146 | Interplay of platelet polymorphisms, risk factors, and Von Willebrand factor, and flow-mediated conditions in determining collagen-adenosine diphosphate PFA-100 results in patients with coronary artery disease. <i>Blood Coagulation and Fibrinolysis</i> , 2005, 16, 97-104. | 1.0 | 6 |
| 147 | The unstable plaque: a broken balance. <i>European Heart Journal</i> , 2009, 30, 1821-1823. | 2.2 | 6 |
| 148 | Antithrombotic Therapy for Patients With Atrial Fibrillation and Atherothrombotic Vascular Disease. <i>Circulation</i> , 2013, 128, 684-686. | 1.6 | 6 |
| 149 | Definición del papel de la oclusión de la orejuela auricular izquierda en la fibrilación auricular. <i>Revista Española De Cardiología</i> , 2013, 66, 79-82. | 1.2 | 6 |
| 150 | Dropping aspirin in patients with atrial fibrillation undergoing percutaneous coronary intervention: a jump with a weak parachute?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 55-56. | 3.0 | 6 |
| 151 | Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention. <i>International Journal of Cardiology</i> , 2021, 337, 1-8. | 1.7 | 6 |
| 152 | Intracranial haemorrhage with bolus thrombolytic agents. <i>Lancet, The</i> , 2000, 356, 1849-1850. | 13.7 | 5 |
| 153 | Reduced CD34+, renal anemia, and adverse outcomes. <i>American Heart Journal</i> , 2006, 152, e21. | 2.7 | 5 |
| 154 | Plasminogen activator inhibitor-1 removal using dextran sulphate columns. Evidence of PAI-1 homeostasis. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 28, 166-172. | 2.1 | 5 |
| 155 | New Anticoagulants and the Future of Cardiology. <i>Revista Española De Cardiología (English Ed)</i> , 2010, 63, 1223-1229. | 0.6 | 5 |
| 156 | Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy. <i>ESC Heart Failure</i> , 2019, 6, 884-888. | 3.1 | 5 |
| 157 | COVID-19 trials in Italy: A call for simplicity, top standards and global pooling. <i>International Journal of Cardiology</i> , 2020, 318, 160-164. | 1.7 | 5 |
| 158 | Trials and tribulations of coronavirus disease-2019 research: with a few bright lights in the fog. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 841-844. | 1.5 | 5 |
| 159 | Prevalence, prescriptions, outcomes and costs of type 2 diabetes patients with or without prior coronary artery disease or stroke: a longitudinal 5-year claims-data analysis of over 7 million inhabitants. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232110263. | 2.5 | 5 |
| 160 | Why Do High-Risk Patients Develop or Not Develop Coronary Artery Disease? Metabolic Insights from the CAPIRE Study. <i>Metabolites</i> , 2022, 12, 123. | 2.9 | 5 |
| 161 | Defining optimal antithrombotic therapy post-TAVI: the contribution of ATLANTIS. <i>European Heart Journal</i> , 2022, 43, 2798-2800. | 2.2 | 5 |
| 162 | Favorable cardiac risk among elderly breast carcinoma survivors. <i>Cancer</i> , 2004, 100, 878-879. | 4.1 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 163 | Asymmetric dimethylarginine and impaired cardiovascular healing. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 27, 168-171. | 2.1 | 4 |
| 164 | Clinical Perspectives and Pearls from the 2015 ESC NSTEMI-ACS Guidelines. <i>Current Cardiology Reports</i> , 2016, 18, 48. | 2.9 | 4 |
| 165 | Prolonged endogenous fibrinolysis predicts reduced survival after acute coronary syndromes. <i>European Heart Journal</i> , 2018, 39, 1086-1088. | 2.2 | 4 |
| 166 | Cardiac mortality, adequate power, and objective inclusion of the entire evidence are key to accurately define the long-term effect of revascularisation vs. medical therapy alone in stable coronary syndromes. <i>European Heart Journal</i> , 2021, 42, 4699-4700. | 2.2 | 4 |
| 167 | High-dose aspirin, thrombin, and coronary angioplasty. <i>Lancet, The</i> , 1993, 341, 1161-1162. | 13.7 | 3 |
| 168 | Platelet and Thrombin Activity Following Cardiac Catheterization Despite Treatment with Aspirin. <i>Journal of Thrombosis and Thrombolysis</i> , 1998, 6, 141-145. | 2.1 | 3 |
| 169 | Testosterone, tissue factor inhibition and vascular aging. <i>Thrombosis and Haemostasis</i> , 2010, 103, 9-10. | 3.4 | 3 |
| 170 | Stroke prevention by low-dose anticoagulation in patients with heart failure and sinus rhythm: is it worth the effort?. <i>European Heart Journal</i> , 2019, 40, 3602-3604. | 2.2 | 3 |
| 171 | When a meta-analysis equals a single large-scale trial with meaningful follow-up. <i>European Heart Journal</i> , 2021, 42, 3884-3885. | 2.2 | 3 |
| 172 | Should we consider low LDL-cholesterol a marker of in-hospital bleeding in patients with acute coronary syndrome undergoing percutaneous coronary intervention?. <i>European Heart Journal</i> , 2021, 42, 3187-3189. | 2.2 | 3 |
| 173 | Closing the Gap Between Populations Enrolled in Traditional Randomized Controlled Trials and Patients Encountered in Clinical Practice: The Case of Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e008840. | 3.9 | 3 |
| 174 | ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrial fibrillation: the (ORIGAMI) study. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 175-179. | 1.5 | 3 |
| 175 | Potential of fibrinolytic therapy in acute myocardial infarction: expanding the role of ACE-inhibitors. <i>Thrombosis and Haemostasis</i> , 2002, 88, 176-8. | 3.4 | 3 |
| 176 | Sex, survival bias, and mortality following acute myocardial infarction. <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , 2003, 4, 508-10. | 0.1 | 3 |
| 177 | Letter by Andreotti et al Regarding Article, "Hemoglobin Level, Chronic Kidney Disease, and the Risks of Death and Hospitalization in Adults With Chronic Heart Failure: The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study"; <i>Circulation</i> , 2007, 115, e313; author reply e314. | 1.6 | 2 |
| 178 | Polycythemia, vascular function, and hemoglobin-nitric oxide reactions. <i>Journal of Applied Physiology</i> , 2011, 111, 331-331. | 2.5 | 2 |
| 179 | Defining the Role of Left Atrial Appendage Closure in Atrial Fibrillation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013, 66, 79-82. | 0.6 | 2 |
| 180 | Stakeholders in NOACs prescription: authors' reply. <i>Europace</i> , 2016, 18, 788.2-789. | 1.7 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 181 | Implantable Cardioverter-Defibrillators for Primary Prevention in Patients With Ischemic or Nonischemic Cardiomyopathy. <i>Annals of Internal Medicine</i> , 2018, 168, 234. | 3.9 | 2 |
| 182 | Aspirin in primary prevention of cardiovascular disease in the elderly. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 326-327. | 3.0 | 2 |
| 183 | Methodological education in response to the quality of COVID-19 publications. <i>Pharmacological Research</i> , 2021, 164, 105381. | 7.1 | 2 |
| 184 | Doppler Ultrasound Monitoring of Echogenicity in Asymptomatic Subcritical Carotid Stenosis and Assessment of Response to Oral Supplementation of Vitamin K2 (PLAK2 Randomized Controlled Trial). <i>Diagnostics</i> , 2021, 11, 229. | 2.6 | 2 |
| 185 | Is it time to introduce anti-inflammatory drugs into secondary cardiovascular prevention: evidence from clinical trials?. <i>Vessel Plus</i> , 0, 2021, . | 0.4 | 2 |
| 186 | Sex- and gender-specific precision medicine for chronic coronary syndromes: challenges and opportunities. <i>Kardiologia Polska</i> , 2021, 79, 373-375. | 0.6 | 2 |
| 187 | Double or triple antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention: not a matter of faith. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e16-e17. | 3.0 | 2 |
| 188 | Different effects of lipopolysaccharide on plasminogen activator inhibitor-1 production in aortic media in vivo and in culture. <i>Journal of Thrombosis and Thrombolysis</i> , 1996, 3, 215-223. | 2.1 | 1 |
| 189 | Comparison of insulin response to intravenous glucose in healed myocardial infarction, in "cooled-off" unstable and stable angina pectoris, and in healthy subjects. <i>American Journal of Cardiology</i> , 1999, 84, 870-875. | 1.6 | 1 |
| 190 | IgA anticardiolipin antibody is associated with the extent of daily-life ischaemia in patients with chronic coronary artery disease. <i>Heart</i> , 2007, 93, 1412-1413. | 2.9 | 1 |
| 191 | Contrast-induced nephropathy and mortality: possible crucial role of asymmetric dimethylarginine. <i>Journal of Cardiovascular Medicine</i> , 2007, 8, 1043. | 1.5 | 1 |
| 192 | Expanding the role of coagulation in arterial thrombosis: Evidence from animal models using a new factor Xa inhibitor. <i>Thrombosis and Haemostasis</i> , 2008, 99, 651-652. | 3.4 | 1 |
| 193 | Hemoglobin Levels, Nitric Oxide Bioavailability and Cardiovascular Outcomes. <i>American Journal of Cardiology</i> , 2011, 107, 1099. | 1.6 | 1 |
| 194 | Data from a multidisciplinary poll of 178 expert physicians on the usage of non-vitamin K Oral Anticoagulants in patients with atrial fibrillation and venous thromboembolism. <i>Data in Brief</i> , 2017, 15, 532-539. | 1.0 | 1 |
| 195 | Diagnoses and outcomes in patients with suspected angina: what are they trying to tell us?. <i>European Heart Journal</i> , 2019, 40, 1436-1439. | 2.2 | 1 |
| 196 | Cancer unmasked by bleeding during anticoagulant therapy: when a problem may become an opportunity. <i>European Heart Journal</i> , 2020, . | 2.2 | 1 |
| 197 | Precision Phenomapping of Acute Coronary Syndromes to Improve Patient Outcomes. <i>Journal of Clinical Medicine</i> , 2021, 10, 1755. | 2.4 | 1 |
| 198 | Efficacy of COVID-19 Vaccines Against Active Comparators or Inert Placebos. <i>JAMA Internal Medicine</i> , 2021, 181, 1257. | 5.1 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 199 | Earlier Recanalisation Follows Bolus Administration of Tissue-Plasminogen Activator in Patients with Acute Myocardial Infarction. <i>Clinical Science</i> , 1989, 76, 37P-37P. | 0.0 | 0 |
| 200 | Key references: Basic fibrinolysis and thrombolysis selected references: 1987-1997. <i>Journal of Thrombosis and Thrombolysis</i> , 2000, 9, 61-68. | 2.1 | 0 |
| 201 | Coronary Artero-Venous Gradient of Endogenous Urokinase. <i>Thrombosis Research</i> , 2001, 103, S29-S34. | 1.7 | 0 |
| 202 | Increased Platelet Reactivity Due to Platelet Receptor Polymorphisms? Not in the Real World. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 1703-1704. | 2.4 | 0 |
| 203 | Substandard life-saving drugs: a global concern. <i>European Heart Journal</i> , 2005, 26, 858-860. | 2.2 | 0 |
| 204 | Intraventricular conduction abnormalities in young patients with type 1 diabetes mellitus. <i>Journal of Cardiovascular Medicine</i> , 2008, 9, 714-715. | 1.5 | 0 |
| 205 | Genetics and Genomics in the Management of Hemostasis and Thrombolysis. , 2010, , 374-389. | | 0 |
| 206 | Last Word on Viewpoint: Anemia contributes to cardiovascular disease through reductions in nitric oxide. <i>Journal of Applied Physiology</i> , 2017, 122, 420-421. | 2.5 | 0 |
| 207 | Meta-analysis of LDL-C Lowering and Mortalityâ€”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1493. | 7.4 | 0 |
| 208 | In replyâ€”â€œReal Worldâ€•TAVR: Data in Constant Flux. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1643-1644. | 3.0 | 0 |
| 209 | Family history in first degree relatives of patients with premature cardiovascular disease. <i>International Journal of Cardiology</i> , 2021, 333, 215-218. | 1.7 | 0 |
| 210 | Updated antithrombotic strategies to reduce the burden of cardiovascular recurrences in patients with chronic coronary syndrome. <i>Biomedicine and Pharmacotherapy</i> , 2021, 140, 111783. | 5.6 | 0 |
| 211 | Unexpected high mortality associated with very low lipoprotein(a) after acute myocardial infarction: Identifying the unknown. <i>European Journal of Internal Medicine</i> , 2021, 91, 26-28. | 2.2 | 0 |
| 212 | Hemostasis and Thrombolysis. , 2009, , 755-772. | | 0 |
| 213 | Circadian fluctuation of fibrinolytic factors in blood. <i>Developments in Cardiovascular Medicine</i> , 1996, , 185-199. | 0.1 | 0 |
| 214 | The strengths and frailties of women with cardiovascular disease. <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , 2003, 4, 361-2. | 0.1 | 0 |